Thryv Therapeutics
PrivateLast Round
Series B
Sep 17, 2025
Total Funding Raised
$41.74M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Thryv Therapeutics is a biotechnology company that develops precision medicine therapies for genetic arrhythmia syndromes, heart failure, and atrial fibrillation using selective SGK1 inhibitors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Thryv Therapeutics Comparables
Compare Thryv Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Acesion Pharma | 81% | |
| Cardurion Pharmaceuticals | 77% | |
| Milestone Pharmaceuticals Inc. | 72% | |
Thryv Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 17, 2025 | ||||
| Convertible Debt | Jun 6, 2023 | ||||
| Series A Extension | Jul 11, 2022 | ||||
| Series A | Aug 10, 2021 | ||||
| Seed | Jan 8, 2020 | ||||
Seed | Nov 6, 2019 |
Thryv Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amzak Health | Series A |
| Investissement Québec | Convertible Debt |
| CTI Life Sciences Fund | Series B |
| Amplitude Ventures | Series B, Series A |
| Investissement Québec | Series B, Convertible Debt |
| Fonds de solidarité FTQ | Series A, Series B, Seed |
| Alexandria Venture Investments | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Drug candidate THRV-1268 designated for Long QT Syndrome treatment.
- Apr 22, 2026
Patient dosing started for THRV-1268 in Wave II study for Long QT Syndrome.
Thryv Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Thryv Therapeutics's valuation, stock price, and market status.